Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database

Gérard et al., Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2145
Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
VigiBase retrospective showing a 20x increase in the risk of acute renal failure with remdesivir.
Gérard, Zhou, Wu show significantly increased risk of acute kidney injury with remdesivir.
Gérard et al., 19 Dec 2020, peer-reviewed, 8 authors.
This PaperRemdesivirAll
Abstract: BRIEF REPORT Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database Alexandre O. Gérard1,2, Audrey Laurain1, Audrey Fresse2, Nadège Parassol2, Marine Muzzone2, Fanny Rocher2, Vincent L.M. Esnault1 and Milou-Daniel Drici2,* Remdesivir is approved for emergency use by the US Food and Drug Administration (FDA) and authorized conditionally by the European Medicines Agency (EMA) for patients with coronavirus disease 2019 (COVID-19). Its benefit-risk ratio is still being explored because data in the field are rather scant. A decrease of the creatinine clearance associated with remdesivir has been inconstantly reported in clinical trials with unclear relevance. Despite these uncertainties, we searched for a potential signal of acute renal failure (ARF) in pharmacovigilance postmarketing data. An analysis of the international pharmacovigilance postmarketing databases (VigiBase) of the World Health Organization (WHO) was performed, using two disproportionality methods. Reporting odds ratio (ROR) compared the number of ARF cases reported with remdesivir, with those reported with other drugs prescribed in comparable situations of COVID-19 (hydroxychloroquine, tocilizumab, and lopinavir/ritonavir). The combination of the terms “acute renal failure” and “remdesivir” yielded a statistically significant disproportionality signal with 138 observed cases instead of the 9 expected. ROR of ARF with remdesivir was 20-fold (20.3; confidence interval 0.95 [15.7–26.3], P < 0.0001]) that of comparative drugs. Based on ARF cases reported in VigiBase, and despite the caveats inherent to COVID-19 circumstances, we detected a statistically significant pharmacovigilance signal of nephrotoxicity associated with remdesivir, deserving a thorough qualitative assessment of all available data. Meanwhile, as recommended in its Summary of Product Characteristics, assessment of patients with COVID-19 renal function should prevail before and during treatment with remdesivir in COVID-19. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  Remdesivir is a nucleoside analog recently approved by the US Food and Drug Administration (FDA) for emergency use and conditionally authorized by the European Medicines Agency (EMA) in patients with coronavirus disease 2019 (COVID-19), although data pertaining to its effectiveness and safety are scant. A decrease of the creatinine clearance has been reported inconstantly in clinical trials. WHAT QUESTION DID THIS STUDY ADDRESS?  Is there a potential signal of a risk of acute renal failure associated with remdesivir in pharmacovigilance postmarketing databases? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?  There is a statistically suggestive disproportionality signal regarding the association of acute renal failure and remdesivir. This possible signal stood out when calculating the reporting odds ratio compared with 3 drugs used in patients with COVID-19. However, many confounding factors persist. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?  These results raise awareness about a possible pharmacovigilance signal regarding the risk of acute renal failure associated with remdesivir, currently being qualitatively explored by regulatory agencies. Meanwhile, close serum creatinine monitoring seems warranted in patients treated with remdesivir. Remdesivir is an antiviral prodrug belonging to the adenosine nucleoside analog family, which is..
{ 'indexed': {'date-parts': [[2022, 3, 15]], 'date-time': '2022-03-15T06:51:49Z', 'timestamp': 1647327109555}, 'reference-count': 26, 'publisher': 'Wiley', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2021, 1, 16]], 'date-time': '2021-01-16T00:00:00Z', 'timestamp': 1610755200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}, { 'start': { 'date-parts': [[2021, 1, 16]], 'date-time': '2021-01-16T00:00:00Z', 'timestamp': 1610755200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'http://doi.wiley.com/10.1002/tdm_license_1.1'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'short-container-title': ['Clin. Pharmacol. Ther.'], 'published-print': {'date-parts': [[2021, 4]]}, 'DOI': '10.1002/cpt.2145', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 12, 19]], 'date-time': '2020-12-19T19:46:41Z', 'timestamp': 1608407201000}, 'page': '1021-1024', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 12, 'title': [ 'Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis ' 'of the WHO Safety Database'], 'prefix': '10.1002', 'volume': '109', 'author': [ { 'given': 'Alexandre O.', 'family': 'Gérard', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Nephrology‐Dialysis‐Transplantation Centre ' 'Hospitalier Universitaire de Nice Nice Cedex France'}, { 'name': 'Department of Pharmacology and Pharmacovigilance Centre ' 'Hospitalier Universitaire de Nice Nice Cedex France'}]}, { 'given': 'Audrey', 'family': 'Laurain', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Nephrology‐Dialysis‐Transplantation Centre ' 'Hospitalier Universitaire de Nice Nice Cedex France'}]}, { 'given': 'Audrey', 'family': 'Fresse', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacology and Pharmacovigilance Centre ' 'Hospitalier Universitaire de Nice Nice Cedex France'}]}, { 'given': 'Nadège', 'family': 'Parassol', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacology and Pharmacovigilance Centre ' 'Hospitalier Universitaire de Nice Nice Cedex France'}]}, { 'given': 'Marine', 'family': 'Muzzone', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacology and Pharmacovigilance Centre ' 'Hospitalier Universitaire de Nice Nice Cedex France'}]}, { 'given': 'Fanny', 'family': 'Rocher', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacology and Pharmacovigilance Centre ' 'Hospitalier Universitaire de Nice Nice Cedex France'}]}, { 'given': 'Vincent L.M.', 'family': 'Esnault', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Nephrology‐Dialysis‐Transplantation Centre ' 'Hospitalier Universitaire de Nice Nice Cedex France'}]}, { 'given': 'Milou‐Daniel', 'family': 'Drici', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacology and Pharmacovigilance Centre ' 'Hospitalier Universitaire de Nice Nice Cedex France'}]}], 'member': '311', 'published-online': {'date-parts': [[2021, 1, 16]]}, 'reference': [ {'key': 'e_1_2_10_1_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/phar.2429'}, {'key': 'e_1_2_10_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v11040326'}, {'key': 'e_1_2_10_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/mBio.00221-18'}, { 'key': 'e_1_2_10_4_1', 'unstructured': 'FDA.Coronavirus (COVID‐19) Update: FDA Issues Emergency Use ' 'Authorization for Potential COVID‐19 Treatment. FDA ' '<https://www.fda.gov/news‐events/press‐announcements/coronavirus‐covid‐19‐update‐fda‐issues‐emergency‐use‐authorization‐potential‐covid‐19‐treatment> ' '(2020).'}, { 'key': 'e_1_2_10_5_1', 'unstructured': 'EMA.First COVID‐19 treatment recommended for EU authorisation. European ' 'Medicines Agency ' '<https://www.ema.europa.eu/en/news/first‐covid‐19‐treatment‐recommended‐eu‐authorisation> ' '(2020).'}, {'key': 'e_1_2_10_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m3049'}, { 'key': 'e_1_2_10_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.biopha.2020.110532'}, { 'key': 'e_1_2_10_8_1', 'unstructured': 'European Medicines Agency.EMA ‐ Summary on compassionate use ‐ ' 'Remdesivir<https://www.ema.europa.eu/en/documents/other/summary‐compassionate‐use‐remdesivir‐gilead_en.pdf> ' '(2020).'}, {'key': 'e_1_2_10_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jps.22109'}, {'key': 'e_1_2_10_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1681/ASN.2020050589'}, {'key': 'e_1_2_10_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1681/ASN.2020040509'}, {'key': 'e_1_2_10_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2015301'}, { 'key': 'e_1_2_10_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phrs.2020.104899'}, { 'key': 'e_1_2_10_14_1', 'article-title': 'Remdesivir for the treatment of Covid‐19 — preliminary report', 'author': 'Beigel J.H.', 'journal-title': 'N. Engl. J. Med.'}, {'key': 'e_1_2_10_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.16349'}, { 'key': 'e_1_2_10_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/009286150804200501'}, {'key': 'e_1_2_10_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s002280050466'}, { 'key': 'e_1_2_10_18_1', 'unstructured': 'Standardised MedDRA Queries | ' 'MedDRA<https://www.meddra.org/standardised‐meddra‐queries>.'}, { 'key': 'e_1_2_10_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2165/00002018-200225060-00010'}, { 'key': 'e_1_2_10_20_1', 'unstructured': 'EMA.Meeting highlights from the Pharmacovigilance Risk Assessment ' 'Committee (PRAC) 28 September ‐ 1 October 2020. European Medicines ' 'Agency ' '<https://www.ema.europa.eu/en/news/meeting‐highlights‐pharmacovigilance‐risk‐assessment‐committee‐prac‐28‐september‐1‐october‐2020> ' '(2020).'}, {'key': 'e_1_2_10_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2011400'}, {'key': 'e_1_2_10_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cgh.2020.07.050'}, {'key': 'e_1_2_10_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jgh.12499'}, { 'key': 'e_1_2_10_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1053/j.ajkd.2005.02.010'}, {'key': 'e_1_2_10_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/pds.995'}, { 'key': 'e_1_2_10_26_1', 'unstructured': 'WHO Collaborating Centre for International Drug Monitoring.Descriptive ' 'analysis of COVID‐19‐related spontaneous reports from VigiBase: interim ' 'results<https://www.who.int/medicines/regulation/medicines‐safety/covid‐19‐pv‐report‐10.pdf> ' '(2020).'}], 'container-title': ['Clinical Pharmacology & Therapeutics'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2145', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cpt.2145', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2145', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 3, 26]], 'date-time': '2021-03-26T11:25:02Z', 'timestamp': 1616757902000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1, 16]]}, 'references-count': 26, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2021, 4]]}}, 'alternative-id': ['10.1002/cpt.2145'], 'URL': 'http://dx.doi.org/10.1002/cpt.2145', 'archive': ['Portico'], 'relation': {}, 'ISSN': ['0009-9236', '1532-6535'], 'issn-type': [{'value': '0009-9236', 'type': 'print'}, {'value': '1532-6535', 'type': 'electronic'}], 'subject': ['Pharmacology (medical)', 'Pharmacology'], 'published': {'date-parts': [[2021, 1, 16]]}, 'assertion': [ { 'value': '2020-10-08', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-12-15', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2021-01-16', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit